Melinta Therapeutics, Inc. (MLNT)
(Delayed Data from NSDQ)
$4.62 USD
+0.38 (8.96%)
Updated May 3, 2019 04:00 PM ET
After-Market: $4.59 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.62 USD
+0.38 (8.96%)
Updated May 3, 2019 04:00 PM ET
After-Market: $4.59 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Melinta Therapeutics, Inc. (MLNT) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Melinta Therapeutics, Inc. (MLNT) delivered earnings and revenue surprises of 10.88% and 2.35%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Melinta Therapeutics, Inc. (MLNT) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
Melinta Therapeutics, Inc. (MLNT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Company News For Oct 28, 2019
by Zacks Equity Research
Companies in the news are: AMZN, BOOM, RMD, MLNT
Implied Volatility Surging for Melinta Therapeutics (MLNT) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Melinta Therapeutics (MLNT) stock based on the movements in the options market lately.
Melinta Therapeutics, Inc. (MLNT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Melinta Therapeutics, Inc. (MLNT) delivered earnings and revenue surprises of -19.46% and 13.96%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Cronos (CRON) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on Cronos' (CRON) regular top and bottom-line numbers along with its pipeline progress when it reports second-quarter results.
Is a Beat in Store for Melinta (MLNT) This Earnings Season?
by Zacks Equity Research
Vabomere and Minocin are expected to drive Melinta's (MLNT) second-quarter revenues. Operating expenses are likely to be lower. The company may provide update on progress of Baxdela label expansion.
Melinta Therapeutics, Inc. (MLNT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Melinta Therapeutics, Inc. (MLNT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Melinta Therapeutics, Inc. (MLNT) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Melinta Therapeutics, Inc. (MLNT) closed at $4.07 in the latest trading session, marking a -0.49% move from the prior day.
Melinta (MLNT) Announces Preliminary Product Sales for Q2
by Zacks Equity Research
Melinta (MLNT) announces preliminary sales for the second quarter. However, sales number suggests estimates miss for the quarter. Shares fall.
Options Traders Expect Huge Moves in Melinta Therapeutics (MLNT) Stock
by Zacks Equity Research
Investors need to pay close attention to Melinta Therapeutics (MLNT) stock based on the movements in the options market lately.
Melinta Therapeutics, Inc. (MLNT) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Melinta Therapeutics, Inc. (MLNT) delivered earnings and revenue surprises of 14.29% and -16.29%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Melinta Therapeutics, Inc. (MLNT) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Melinta Therapeutics, Inc. (MLNT) delivered earnings and revenue surprises of -91.09% and 99.76%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
TherapeuticsMD (TXMD) Catches Eye: Stock Jumps 6.1%
by Zacks Equity Research
TherapeuticsMD (TXMD) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Adamis Pharmaceuticals (ADMP) Jumps: Stock Rises 5.3%
by Zacks Equity Research
Adamis Pharmaceuticals (ADMP) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Jazz (JAZZ) Increases Share Buyback Authorization by $400M
by Zacks Equity Research
Jazz's (JAZZ) board sanctions a raise in its share buyback authorization by $400 million.
Nektar (NKTR) Catches Eye: Stock Jumps 8.7%
by Zacks Equity Research
Nektar (NKTR) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Melinta Therapeutics, Inc. (MLNT) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Melinta Therapeutics, Inc. (MLNT) delivered earnings and revenue surprises of 52.38% and 97.63%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Melinta Therapeutics, Inc. (MLNT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Melinta Therapeutics, Inc. (MLNT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Melinta Therapeutics, Inc. (MLNT) Q3 Earnings Preview: What to Know Ahead of the Release
by Zacks Equity Research
Melinta Therapeutics, Inc. (MLNT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Melinta Therapeutics, Inc. (MLNT) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Melinta Therapeutics, Inc. (MLNT) delivered earnings and revenue surprises of -32.69% and -0.32%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Medicines Company to Sell Infectious Disease Unit to Melinta
by Zacks Equity Research
The Medicine Company (MDCO) has signed an agreement with Melinta to sell its infectious disease unit in a cash and stock transaction.
Why Earnings Season Could Be Great for Cempra (MLNT)
by Zacks Equity Research
Cempra (MLNT) is seeing encouraging earnings estimate revision activity as of late and carries a favorable rank, positioning the company for a likely beat this season.